| Literature DB >> 29460083 |
Abstract
Background Renal elimination normally decreases with age. Nonsteroidal antiinflammatory drugs (NSAIDs) carry a risk of additional kidney damage. Objective The aims of this study were to assess the prevalence of NSAIDs in the elderly (aged ≥ 65) population in Sweden, explore reasons for any possible differences in the level of use and assess their kidney functions. Setting Data were obtained from the cohort study Good Aging in Skåne, Sweden. Patients aged 65 or more were included. Methods Medication lists were collected as well as variables such as cognition and education levels. Glomerular filtration rate was estimated from creatinine and cystatin C. Descriptive statistics and multiple linear regression analysis were used. MAIN OUTCOME MEASURE: NSAID use among the general elderly population. Results A total of 1798 patients were included. Approximately six percent (n = 105) of the people in the study group were using NSAIDs and of those 82 (78%) bought NSAIDs over the counter (OTC). 42% of those buying NSAIDs OTC showed an estimated glomerular filtration rate below 60 ml/min/1.73 m2. Education level did not affect the use of nonsteroidal anti-inflammatory drugs, nor did age. NSAIDs were more commonly used than other recommended analgesics. Conclusion Many people are unaware of the risks associated with the use of NSAIDs. The findings imply that the frailest elderly use NSAIDs to the same extent as the younger elderly do. It is important that information about safety of these drugs be communicated to both patients and healthcare professionals.Entities:
Keywords: Anti-inflammatory agents; Elderly; Glomerular filtration rate; NSAID; Risk; Sweden
Mesh:
Substances:
Year: 2018 PMID: 29460083 PMCID: PMC6132969 DOI: 10.1007/s11096-018-0598-8
Source DB: PubMed Journal: Int J Clin Pharm
Active substances for systemic use (ATC groups), that were included in the analysis
| NSAIDs | M01AB01 | Indometacin |
| M01AB05 | Diclofenacb | |
| M01AB15 | Ketorolac | |
| M01AB55 | Diclofenac, combinations | |
| M01AC01 | Piroxicam | |
| M01AC02 | Tenoxicam | |
| M01AC05 | Lornoxicam | |
| M01AC06 | Meloxicam | |
| M01AE01 | Ibuprofena | |
| M01AE02 | Naproxena | |
| M01AE03 | Ketoprofen | |
| M01AE14 | Dexibuprofen | |
| M01AE17 | Dexketoprofen | |
| M01AE51 | Ibuprofen, combinations | |
| M01AE52 | Naproxen/esomeprazole | |
| M01AH01 | Celecoxib | |
| M01AH04 | Parecoxib | |
| M01AH05 | Etoricoxib | |
| M01AX01 | Nabumetone | |
| Other analgesics | ||
| Paracetamol | N02BE01 | Paracetamola |
| Opioids | N02AA01 | Morphine |
| N02AA03 | Hydromorphone | |
| N02AA05 | Oxicodone | |
| N02AA55 | Oxicodone, combinations | |
| N02AA59 | Codeine, combinations | |
| N02AB01 | Ketobemidone | |
| N02AB03 | Fentanyl | |
| N02AE01 | Buprenorphine | |
| N02AG01 | Morphine and spasmolytica | |
| N02AG02 | Ketobemidone and spasmolytica | |
| N02AX02 | Tramadol | |
| N02AX06 | Tapentadol | |
| Drugs for neuropathic pain | N03AX12 | Gabapentin |
| N06AA09 | Amitriptyline | |
| N06AX21 | Duloxetine | |
aDrugs for systemic use available OTC outside pharmacies (for paracetamol only other formulations than tablet since 2015)
bDrugs for systemic use available without prescription, though only at pharmacies
Background characteristics for the study population
| N = 1832a | n | Minimum | Maximum | Mean | SD |
|---|---|---|---|---|---|
| Age | 1798 | 64 | 101 | 75 | 9.15 |
| p-creatinine (µmol/l) | 1574 | 41 | 409 | 86 | 29.4 |
| p-cystatine C (mg/l) | 1574 | 0.61 | 5.89 | 1.14 | 0.43 |
| eGFR LMrev (ml/min/1.73 m2) | 1574 | 10.1 | 107 | 61.5 | 15.1 |
| eGFR capa (ml/min/1.73 m2) | 1574 | 5.0 | 126 | 68.1 | 20.3 |
| eGFR mean (ml/min/1.73 m2) | 1574 | 9.5 | 103 | 64.8 | 17.0 |
| Mini-mental test, sum | 1602 | 5 | 30 | 26.7 | 2.98 |
aDate for examination was missing for 34 cases
The use of NSAIDs (regularly or as needed) within the groups of different CKD-stages
| NSAID use, n (%) | NSAID prescribed by physician, n (%) | NSAID use OTC, n (%) | |
|---|---|---|---|
| Study population, total (N = 1798) | 105 (5.8) | 23 (1.3) | 82 (4.6) |
| CKD grade (n = 1574)a | |||
| 1–2 (eGFR ≥ 60 ml/min/1.73 m2) | 57 (3.6) | 14 (0.9) | 43 (2.7) |
| 3 (eGFR 30–59 ml/min/1.73 m2) | 39 (2.5) | 8 (0.5) | 31 (2.0) |
| 4–5 (eGFR < 30 ml/min/1.73 m2) | 0 (0) | 0 (0) | 0 (0) |
aeGFR was missing for 224 people